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Giovanni Colombo6, Piero Picozzi1-BACKGROUND: Short-lasting unilateral neuralgiform headache attacks with
conjunctival injection and tearing (SUNCT) is a primary headache syndrome
with an unclear pathogenesis, and only in very few cases, SUNCT is secondary
to known lesions (secondary SUNCT). Several pharmacological as well as
interventional and invasive treatments have been used to treat SUNT cases, with
no definitive results. We describe a patient with idiopathic SUNCT syndrome,
successfully treated with gamma knife radiosurgery and we report a review of
the cases of the literature treated with radiosurgery.
-CASE REPORT: A 63-year-old woman complained of episodes of intense and
regular paroxysmal facial pain in the territory of the maxillary branch of the
trigeminal nerve accompanied by inflammation of conjunctiva and involuntary
lacrimation from 2006. During the following years, she received several treat-
ments: combination of drugs, acupuncture, and endonasal infiltration of the
sphenopalatine ganglion. The frequency of the painful attacks increased pro-
gressively and it was impossible for her to have a normal active life. Combined
gamma knife radiosurgery treatment, targeting the trigeminal nerve (80 Gy
maximum dose) and the sphenopalatine ganglion (80 Gy maximum dose) was
performed in April 2016 (visual analog score before treatment [ 6). Pain
gradually reduced in the following months, as well as frequency and severity of
the attacks. No sensory deficit developed. The follow-up length of our patient is
37 months: she is nearly pain free (visual analog score[ 2) and has resumed a
normal life.
-CONCLUSIONS: Patients with idiopathic SUNCT have few therapeutic op-
tions. Our case demonstrates that gamma knife radiosurgery is a feasible and
effective noninvasive option to treat patients with medically refractory idio-
pathic SUNCT.
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Short-lasting unilateral neuralgiform
headache attacks with conjunctival injec-
tion and tearing (SUNCT) syndrome is a
rare pathology, defined as a primary
headache syndrome.1,2 SUNCT diagnosis
can be difficult because signs and
symptoms overlap with other facial pain
diseases, such as trigeminal neuralgia
and cluster headache. This pathology is
characterized by at least 20 pain attacks
per day, with a wide range of duration
(1e600 seconds). The SUNCT attacks
usually start and cease abruptly and have
an irregular temporal pattern. The
rights reserved.WORLD NEUROSURGERY 133: 167-171,localization of such attacks is
characteristic because they are mainly
unilateral and affect the orbital/
periorbital region. As the name of the
syndrome indicates, these painful
attacks, which can be moderate or
severe, are followed by dramatic
conjunctival injection and lacrimation.1,2
Signs and symptoms are not limited to
those described here. During the attacks,
rhinorrhea or nasal stuffiness, facial
sweating, hyperventilation, and increased
intraocular pressure on the symptomatic
side, as well as vascular engorgementJANUARY 2020 www.journals.eland eyelid edema with pseudoptosis can
also occur.2,3 Ictal changes in pupillary
diameter are rare in SUNCT.
The pain has been described as burning,
stabbing, or electric in character. Pain at-
tacks start and cease abruptly, without any
premonitory sign. In some cases, these at-
tacks are triggered by external factors, such
as a change of temperature. Postattack re-
fractory periodsmay be completely absent.4
Solitary attacks usually have a “plateau-
like” pattern, but other temporal patterns
can be seen: repetitive (short-lasting
attacks in rapid succession), sawtooth-likesevier.com/world-neurosurgery 167
Figure 1. Gamma knife radiosurgery targets on magnetic resonance imaging. (A) Trigeminal nerve. (B) Sphenopalatine ganglion (see text for details).
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consecutive spike-like paroxysms occur
without reaching the pain-free baseline),
and plateau-like plus exacerbations (a
mixture of 1- to 2-second jabs super-
imposed on top of the conventional
plateau-like pattern).4
The etiology and pathogenesis of
SUNCT is unknown. SUNCT syndrome is
more frequently idiopathic, and in very few
cases can be secondary to other pathol-
ogies.5 IthasbeenhypothesizedthatSUNCT
symptoms arise from the triggering of
the trigeminally innervated areas, even
though it has also been reported that
extratrigeminal territory can be involved.6
The SUNCT syndrome is a lifelong
condition, and patients can need treat-
ment for an indefinite period. Until now,
no consensus has emerged to define the
effective treatment. Pharmacological as
well as interventional and invasive treat-
ments have been performed, with no
definitive results.7
Here we describe a case of idiopathic
SUNCT syndrome successfully treated168 www.SCIENCEDIRECT.comwith gamma knife radiosurgery (GKRS)
targeting the trigeminal nerve and sphe-
nopalatine ganglion and review the cases
of the literature reporting radiosurgical
treatment for such a rare disease.CASE REPORT
A 63-year-old woman, suffering from
SUNCT dating from the age of 52 years,
was referred to our University Hospital.
Apart from the painful syndrome, the pa-
tient was healthy and had no significant
medical history. The pain syndrome star-
ted in 2006 (winter) and was mainly
localized in the territory innervated by the
maxillary branch (V2) of the right trigem-
inal nerve (TN). The patient reported that
the pain attacks were often triggered by
any kind of stimulation in the TN territory
(tactile, motor, or gustative stimuli);
however, on several occasions she could
not individualize any apparent trigger. The
pain attack was always accompanied by
rapidly developing conjunctival injection
and lacrimation in the right eye. TheWORLD NEUROSURGERY, httppatient underwent several odontoiatry
evaluations, which did not show any pa-
thology in the upper right jaw (V2 inner-
vation area). She started to wear a dental
mouthguard, which did not have any effect
on the pain attacks. In July 2006, the pa-
tient started acupuncture treatment 2
times a week, with very little reduction in
the pain attacks. In September 2006, she
started medical treatment with progressive
doses of amitriptyline (up to a maximal
dosage of 100 mg/day) with a short-term
benefit of the pain attacks, but long-term
gain in aqueous humor control. Mean-
while, she also started steroids and vita-
mins (B12, B1, B6, niacin, vitamin E),
without evident benefits.
In the following years, she underwent
cutaneous electrostimulation in 2010, and
in the same year, the ear, nose, and throat
surgeon applied a mixture of cocaine,
menthol, and phenol together with ampi-
cillin and steroids at the level of the right
sphenopalatine ganglion (SPG), without
pain relief. After an extremely distressing
pain attack in May 2011, she starteds://doi.org/10.1016/j.wneu.2019.10.016
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Figure 2. PRISMA flow diagram.
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After another worsening in 2013, hydro-
morphone was changed for oxycodone
and naloxone, and the patient underwent
lidocaine infiltrations of the right SPG.
There was a further worsening in the next
year; she was then suffering pain attacks
almost every hour. In October 2014,
gabapentin was introduced in the therapy
with no pain improvement.
In 2016, she was referred to our Uni-
versity Hospital and underwent radio-
surgery treatment that was performed
using GKRS, with the help of both mag-
netic resonance imaging (MRI) and
computed tomography (CT) targeting.
Because of similarities between SUNCT
and cluster headache, it was decided to
treat both the trigeminal nerve and the
sphenopalatine ganglion. A Leksell G
stereotactic frame was attached to the
patient’s head under local anesthesia and
conscious sedation (e.g., midazolam).
Thereafter, a 1-mm-thick axial contrast-
enhanced T1 volumetric MRI sequence, aWORLD NEUROSURGERY 133: 167-171,FIESTA T2 sequence and CT scan for bone
imaging were obtained for trigeminal root
and sphenopalatine ganglion localization,
and treatment planning (Figure 1).
Radiosurgery was performed with a
Gamma Knife Perfexion (Elekta
Instruments, Stockholm, Sweden). The
TN was targeted at the level of the
intracisternal segment using a single 4-
mm isocenter delivering 80 Gy
(maximum dose). Because of the small
dimension of the cistern and the short
length of the nerve in this particular pa-
tient, the 4-mm isocenter was plugged to
keep the 15-Gy isodose out of the brain-
stem. The SPG was targeted with the
assistance of a neuroradiologist and an
ear, nose, and throat surgeon. Because the
SPG is not directly visible on CT and MRI
scans, the posterior part of the pter-
ygopalatine fossa, where the vidian nerve
terminates in the ganglion, was targeted.
The V2 also passes through the pter-
ygopalatine fossa and has multiple anas-
tomoses with the SPG. This region wasJANUARY 2020 www.journals.eltargeted with a single 8-mm isocenter
delivering a maximum dose of 80 Gy. The
use of a wider isocenter for this target is
related to the difficulty to precisely identify
the sphenopalatine ganglion, as well as to
the absence of other sensitive structures in
this anatomical region.8,9
At the first follow-up, 3 months after the
radiosurgical procedure, the patient re-
ported a significant reduction of the pain,
which nearly completely disappeared 6
months after radiosurgery. There was no
alteration in facial sensation. On the latest
follow-up, 37 months after the procedure,
the patient remains completely pain free
(visual analog scale ¼ 2), and she only
uses amitriptyline 10 mg twice daily. She
did not suffer from any side effect or
complication from the procedure.REVIEW OF THE LITERATURE
To assess the use of radiosurgery for the
treatment of primary SUNCT syndrome,
the authors performed a systematic review
of the literature up to May 2019, using the
MEDLINE and SCOPUS databases. The
following keywords terms were used in a
title and abstract screening: “Short-lasting
Unilateral Neuralgiform Headache attacks
with Conjunctival injection and Tearing,”
“SUNCT,” “SUNCT and treatment,”
“SUNCT and radiosurgery.” Relevant ref-
erences of published articles were
screened to increase the scientific quality
of papers.
The selection of the papers has been
summarized in the PRISMA flowchart
(Figure 2). According to our review, only 5
patients with SUNCT treated with
radiosurgery have been reported up to
now.10-13 In 2002, Black and Dodick
reported the first 2 SUNCT patients
treated with radiosurgery.10 Both patients
had failed medical therapies. The first
patient underwent a glycerol rhizotomy,
GKRS, and microvascular decompression
of the TN. The second patient underwent
GKRS of the trigeminal root exit zone
and 2 microvascular decompression
surgeries. Both patients received GKRS
treatment targeting the trigeminal nerve
only, and neither patient benefited from
radiosurgery. Subsequent reports of
idiopathic SUNCT cases documented that
radiosurgery treatment was beneficial.11-13
Effendi et al. reported a case in 2011 of
SUNCT successfully treated by GKRSsevier.com/world-neurosurgery 169
Table 1. Cases of Idiopathic SUNCT Syndrome Treated With Radiosurgery
Author Year Sex Age
Years From
Presentation Duration (s)
Frequency
(Per d) Trigger Pain Side Target Dose (Gy) Follow-Up (mo) Success
Black et al. 2002 M 39 2 2e3 20e400 NA R TN 90 Gy NA No
M 28 10 20e30 100e200 NA R TN 90 Gy NA No
Effendi et al. 2011 M 82 6 30e120 3e10 Yes R TN
SPG
80 Gy
80 Gy
39 Yes
Mathew et al. 2012 M 50 1 10e30 100e200 NA R TN
SPG
80 Gy
80 Gy
4 Yes
Tan et al. 2013 F 83 1 300e1800 6e10 Yes R TN
SPG
90 Gy
80 Gy
16 Yes
Present study 2019 F 63 10 20e120 >100 Yes R TN
SPG
80 Gy
80 Gy
37 Yes
NA, not available; R, right; SPG, Sphenopalatine ganglion; TN, Trigeminal nerve.
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ISMAIL ZAED ET AL. TARGETING THE TRIGEMINAL NERVE AND THE SPHENOPALATINE GANGLIONwith irradiation of both the trigeminal
nerve and sphenopalatine ganglion. A
dose of 80 Gy was delivered to both
structures. The patient did not have any
side effects from the procedure, had
complete pain cessation 2 weeks after
the treatment, and remained pain-free
with no medication at the latest follow-
up (39 months after radiosurgery).11 A
similar case was reported in 2012. A 50-
year-old man with SUNCT refractory to
medications received GKRS treatment.12
He was given 80 Gy both to the
trigeminal nerve and the sphenopalatine
ganglion. At 4 months’ follow-up, he had
no more spontaneous attacks and only
very occasional brief episodes of pain,
precipitated by touching. GKRS of both
the trigeminal nerve and sphenopalatine
ganglion yielded near-total relief to the
patient. In 2013, Tan et al.13 treated a
SUNCT case with frameless stereotactic
radiosurgery targeting the trigeminal
nerve and the sphenopalatine ganglion.
A total dose of 90 Gy was prescribed to
the isocenter for the trigeminal nerve and
80 Gy was prescribed to the isocenter for
the sphenopalatine ganglion. At 1 week
posttreatment, the 83-year-old patient
reported a 60% reduction of pain. Her
pain continued to improve and at her
last follow-up (16 months), she was
completely pain free without any
medications.13
Table 1 illustrates the SUNCT cases
treated with stereotactic radiosurgery. All
but 2 patients were male, and the mean
age was 57.5 years (range, 28e83). There170 www.SCIENCEDIRECT.comwas a great range of variability both in
the duration of the pain attacks (from 2
up to 1800 seconds), and in the
frequency (from 3 to 400 attacks per
day). In all cases, the pain was localized
on the right side, and in 50% of the
cases (3 of 6), the pain attacks were
triggered. Radiosurgical treatment was
effective in 4 of 6 patients (this
study).11-13 The 2 cases reported by Black
et al.10 did not show any significant
improvement after radiosurgery
treatment. The authors did not give any
explanation for the failures; however, in
both cases, only the entry root of the
trigeminal nerve was irradiated, without
targeting the sphenopalatine ganglion. In
the cases in which both the TN and SPG
were treated (4 of 6 patients), the same
dosage (80 Gy) was used to treat the
trigeminal nerve and the sphenopalatine
ganglion and the radiosurgery treatment
was effective (this study).11-13 These case
reports also demonstrate that both
targets can be treated safely with
minimal side effects for the patient.DISCUSSION
According to a recent classification of
headache disorders, SUNCT syndrome is
defined as a rare trigeminal autonomic
cephalalgia, characterized by attacks of
moderate or severe strictly unilateral neu-
ralgiform paroxysmal orbital, supraorbital
or temporal and/or other trigeminal dis-
tribution stabbing pain lasting for 1 to 600
seconds.1 The pain symptoms areWORLD NEUROSURGERY, httpaccompanied by ipsilateral cranial
autonomic features such as lacrimation
and conjunctival injection.1-4,6 Although
SUNCT is classified as a primary
headache disorder, secondary causes
have been increasingly reported, such as
neoplastic lesions in the posterior fossa,
pituitary gland, and also neurovascular
conflicts and infections.5
The proposed pathophysiology of
SUNCT is the activation of the trigeminal
autonomic reflex and the trigeminal cer-
vical complex, which are both responsible
for the autonomic symptoms and the
debilitating pain.1,14 Furthermore, SUNCT
has similarities with cluster headache, and
high-frequency stimulation of the sphe-
nopalatine ganglion is an emerging abor-
tive treatment for cluster headache
attacks.15 These pathophysiological
considerations constitute the scientific
basis for the combined treatment of the
trigeminal nerve and the sphenopalatine
ganglion. For the treatment of trigeminal
neuralgia, the TN has been frequently
targeted with radiosurgery in its
intracisternal component. In recent years,
the technique has been refined and great
care is taken to target the precise area to
be treated to optimize pain control and
minimize complications.16 It has been
reported that a lesion close to the root
exit zone of the TN is very effective on
pain, although this type of lesion carries
the possibility of unpleasant collateral
symptoms (hypoesthesia). Therefore,
when feasible and depending on
intracisternal TN length, the isocenters://doi.org/10.1016/j.wneu.2019.10.016
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brainstem16; doses generally used for
these treatments range between 80 and
90 Gy (maximal dose).15,16
The other target, the SPG, is a relay
for the autonomic fibers toward the
lacrimal and nasal mucosal glands. The
pterygopalatine fossa, where the SPG is
located, establishes connections with the
maxillary branch of the TN. Thus, it
makes sense to select this target for
therapeutical procedures, such as local
drug infiltration or stimulating electrode
insertion or neurodestructive procedure
in SUNCT cases.
According to our review, very few pa-
tients have been treated with radiosurgery
for such rare syndrome with mixed re-
sults.10-13 The SUNCT patients who did
benefit from radiosurgery received treat-
ment targeting both the TN and the SPG,
demonstrating that the irradiation of the
SPG is fundamental for the control of pain
in the SUNCT syndrome.11-13 It has been
postulated that the addition of the SPG in
combination with the TN as a target might
have been important for complete pain
relief, because efferent parasympathetic
outflow from it may be involved in further
pain generation through the activation of
trigeminovascular sensory afferents.15
Thus, by ablating both targets, one
might achieve peripheral blockade of all
possible pain pathways, providing
effective pain relief for the patient. The
case reports have also demonstrated that
both targets can be treated safely with
minimal side effects for the patient.11-13
Our patient has been followed for more
than 3 years; however, a longer follow-up
will be necessary to evaluate the long-
lasting effects of such an approach. If
she remains pain free, GKRS targeting
trigeminal nerve and sphenopalatine gan-
glion may provide a very attractive treat-
ment option for the patient who suffers
from medically refractory SUNCT.WORLD NEUROSURGERY 133: 167-171,CONCLUSIONS
SUNCT is a rare but debilitating cephalalgia
that is difficult to control. It can be idio-
pathic or secondary to other pathologies.
After failed medical therapy, options
include nerve blockades, sphenopalatine
ganglion stimulation, microvascular sur-
gery, or other neurosurgical procedures,
depending on the secondary cause of the
syndrome. Up to now, to the best of our
knowledge, these options are all invasive to
various degrees.
Here we present a case of idiopathic
SUNCT syndrome, successfully treated
using GKRS, a minimally invasive pro-
cedure. Initial response to treatment has
been excellent, with no side effects.
Longer follow-up and further experience
with radiosurgery will determine the effi-
cacy and safety of this treatment option for
such a rare disease.
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